Form 4: Royalty Pharma EVP Marshall Urist Acquires Shares

Royalty Pharma executive Marshall Urist acquired 18,197 Class A Ordinary Shares through the settlement of equity performance awards.

Summary

• Marshall Urist, EVP of Research & Investments at Royalty Pharma, acquired 18,197 Class A Ordinary Shares on May 6, 2026.
• The acquisition was part of an exempt settlement of equity performance awards.
• Following the transaction, Urist holds 45,565 shares directly and 19,020 shares indirectly via an IRA.
• The reporting person also maintains significant indirect interests in exchangeable partnership and holding company shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing documenting standard executive compensation settlement.

Positives

• The acquisition reflects the executive's continued alignment with the company through equity-based compensation.

Negatives

• None identified.

Risks

• The value of the holdings is subject to market fluctuations in Royalty Pharma's share price.
• Class E Ordinary Shares held by the reporting person remain subject to vesting conditions.

Future Outlook

No specific forward-looking guidance regarding company performance was provided in this filing.

Management Comments

• The transaction reflects the settlement of Equity Performance Awards.

Industry Context

StockSavvy.ai notes that insider equity settlements are standard corporate governance practices used to align executive compensation with long-term shareholder value in the biopharmaceutical royalty sector.

Comparison to Industry Standards

• The use of equity performance awards for executive compensation is consistent with standard practices among large-cap biopharmaceutical and investment firms.
• The reporting of these transactions via Form 4 complies with standard SEC regulatory requirements for corporate insiders.

Stakeholder Impact

• The transaction has no material impact on shareholders, employees, or creditors as it represents a routine settlement of existing compensation agreements.

Next Steps

• Continued monitoring of future Form 4 filings for changes in executive ownership.

Key Dates

Keywords

Royalty Pharma, RPRX, Insider Transaction, Form 4, Equity Compensation, Marshall Urist